Longer-term findings from the phase 2 ARACOG study suggest differences in objectively measured cognitive function between ARPIs.
|Articles|November 1, 2003
HIFU yields 73% cancer-free rate at 6 months
Author(s)Robert H. Carlson
Chicago-Treating localized prostate cancer with high-intensityfocused ultrasound (HIFU) appears to be safe, efficacious, and well tolerated,according to data presented by several European research groups at the AUAannual meeting in Chicago.
Advertisement
Advertisement
Related to this article
Engy Habashy, MD, discusses key takeaways from the 2025 AUA GSM guideline, including the role of androgens and hormonal therapies in managing genitourinary syndrome of menopause.
Chad R. Ritch, MD, MBA, FACS, discusses how PSMA-PET informs staging, treatment planning, recurrence workup, and the interpretation of equivocal findings.
Michael S. Cookson, MD, MMHC, FACS, discusses how Anktiva’s expanded FDA approval may broaden bladder-preserving treatment options for BCG-unresponsive papillary-only NMIBC.
Jeffrey M. Spier, MD, discusses how fatigue may impact patient quality-of-life and when dose reduction may be an appropriate treatment strategy.
This approval expands the perioperative use of pembrolizumab plus enfortumab vedotin to all patients with MIBC, regardless of cisplatin eligibility.
Take a look through some of the notable data presentations at this year's ESMO Congress.
The investigational HIF-2α inhibitor casdatifan demonstrated antitumor activity as monotherapy and in combination regimens across the ARC-20 platform study.
Advertisement
Advertisement
Trending on Urology Times
1
How PSMA-PET shapes staging and recurrence workup in prostate cancer
2
ESMO 2026: Key presentations across genitourinary oncology
3
European Commission approves perioperative pembrolizumab plus enfortumab vedotin for MIBC
4
Engy Habashy, MD, on the role of androgens in GSM management
5